Are Peptides Legal? The 2026 US Regulatory Status, Explained

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

"Are peptides legal" has no single answer, because a peptide is not one legal thing. The word covers an FDA-approved drug like insulin, a compound a pharmacy prepares against a prescription, and a vial sold for laboratory research. US law treats those three situations very differently. This page sorts peptides into the three categories that decide legality, explains what each one means in 2026, and corrects the claims circulating after this year's regulatory news. It is a regulatory-status reference rather than buying or medical guidance. The compounding side is covered in depth across a set of companion explainers, linked throughout.

Are peptides legal? The short answer

Legality depends entirely on how a specific peptide is classified, made, and sold. In practice, US regulatory lawyers sort peptides into three buckets. This is a working taxonomy rather than a list written into the statute, but it maps cleanly to how the law actually applies.

• FDA-approved peptide drugs. Fully legal as prescription drugs, manufactured under current good manufacturing practice. Examples include insulin, semaglutide, liraglutide, tirzepatide, and tesamorelin. The FDA has approved roughly eighty to one hundred peptide drugs. [1]
• Compounded peptides. Lawful for a 503A pharmacy or 503B outsourcing facility to prepare against a valid prescription when the substance is eligible, but not FDA-approved. Compoundable does not mean approved.
• Research-use-only peptides. Lawful to sell and possess for bona fide laboratory research, but not approved or legal for human consumption. The research-use label alone does not make human use lawful. [2]

The rest of this page works through each category, then covers what changed in 2026, sport and anti-doping, state and import rules, and how to check a specific peptide.

Category one: FDA-approved peptide drugs

The clearest case is a peptide the FDA has reviewed and approved as a drug. Insulin, approved as far back as the 1920s, is the classic example. The modern wave is the GLP-1 class, including semaglutide and tirzepatide, alongside others such as liraglutide and tesamorelin. Peer-reviewed reviews put the number of FDA-approved peptide drugs at around one hundred. [1]

These are legal in the ordinary way any prescription drug is legal. They are made under current good manufacturing practice, carry an approved label with studied indications, and are dispensed by licensed pharmacies against a prescription. Nothing about the 2026 peptide news changes their status, and they sit outside the controversy that surrounds the other two categories.

Category two: compounded peptides

A compounding pharmacy can prepare a medication that is not a mass-produced approved drug. Two kinds of compounder exist: a 503A pharmacy, which prepares a preparation against a prescription for a specific patient, and a 503B outsourcing facility, which produces larger batches under current good manufacturing practice. The difference between the two, and which one a given peptide could move through, is covered in the 503A versus 503B explainer, and what a 503A pharmacy is in the 503A compounding pharmacy explainer.

The point that matters for legality is this: a peptide being eligible for compounding is not the same as the peptide being FDA-approved. A compounded preparation has not been through the approval process; it is permitted under the narrower compounding rules. Whether a specific peptide is even eligible to be compounded depends on the FDA's interim bulk-substance categories, which are under active review. Where each peptide stands is tracked in the 503A bulks-list status board. The shorthand worth remembering is that compoundable does not mean approved, and that distinction is the source of most of the confusion in the headlines.

Category three: research-use-only peptides

The third category is where most of the peptides discussed online actually sit, and where the law is most widely misread. A peptide sold and labeled for research use only is lawful to sell and possess for genuine laboratory research. It is not approved, and it is not legal, for human consumption.

The mechanism behind that line is the intended-use doctrine. Under the Federal Food, Drug, and Cosmetic Act, a product becomes a drug the moment it is intended to affect the structure or function of the body, and an unapproved new drug cannot be introduced into interstate commerce. [3] [4] The FDA's intended-use regulation establishes that intent from the totality of the circumstances: the labeling, the marketing claims, written and spoken statements, and even the way a product is distributed. [2] A research-use-only label is therefore not a safe harbor. If a seller pairs the disclaimer with therapeutic claims, dosing guidance, or human-use signals, the FDA can treat the product as an illegally marketed unapproved drug despite the label.

This is not theoretical. On March 31, 2026, the FDA issued warning letters to seven companies selling research-labeled peptides, stating that despite the research-use language, evidence from the companies' own websites established that the products were intended as drugs for human use. [5] The practical reading is that the legality of a research-use peptide depends on it being sold and used as what it says it is. It is also why responsible research-use material is presented without human-use claims, which is the standard this publication holds itself to.

What actually changed in 2026

Several headlines this year suggested peptides were "becoming legal again." The reality is narrower and worth stating precisely, because the popular framing is largely inverted.

In February 2026, the Secretary of Health and Human Services said in a podcast interview that the FDA intended to move about fourteen of the peptides on its restricted compounding list toward the less-restricted category. A statement of intent on a podcast is not a rule, and it is not approval. [6] What the FDA has actually done is procedural. In September 2023, more than a dozen nominated peptides were placed in the interim Category 2, the bucket flagged for significant safety concerns. In April 2026, twelve peptides were removed from Category 2 by accepting the withdrawal of their nominations, and seven of those were referred to the Pharmacy Compounding Advisory Committee for a meeting on July 23 and 24, 2026. [7]

None of that is legalization. Removal from Category 2 does not place a peptide on the approved list, and the July meeting produces a recommendation, not a rule. The full picture of that meeting is in the July 2026 advisory committee explainer. The takeaway for the legality question is that the 2026 activity affects the compounding category only, and even there it changes eligibility rather than conferring approval.

Peptides in sport and anti-doping

A separate legal layer applies to athletes. Many of the peptides discussed in wellness settings are banned in regulated sport regardless of their FDA status. BPC-157 is listed under the World Anti-Doping Agency's S0 class for non-approved substances, prohibited at all times. [8] TB-500 and the broader class of growth and repair peptides are prohibited as well, classified under S0 or under S2 for peptide hormones and growth factors depending on the substance. An athlete subject to anti-doping rules can face sanction for these regardless of how the peptide was obtained, which is one more reason human use sits outside the scope of research-use material.

State rules and importation

Two further layers narrow the picture. At the state level, pharmacy boards have layered their own restrictions onto compounded peptides, with some states requiring documented clinical justification, restricting non-approved-drug labeling, or limiting out-of-state dispensing. The federal categories above are the floor, and individual states can be stricter.

On importation, the FDA treats most non-pharmaceutical peptides as unapproved new drugs, so personal importation is generally unlawful and runs on narrow enforcement discretion rather than a right. Import alerts have tightened since 2023: Import Alert 66-78 was expanded in 2025 to add additional peptides, allowing shipments to be detained without physical examination, and a related alert covering GLP-1 bulk substances was revised in 2026. [9] The trend points toward stricter enforcement rather than looser.

How to check a specific peptide's legal status

The status of any one peptide can be established from primary sources. First, check whether it is an FDA-approved drug; approved peptide drugs appear in the FDA's approved-drug records. Second, if it is discussed as a compounded peptide, check its interim category on the FDA's bulk-substances materials, tracked for the peptides under review in the 503A bulks-list status board. Third, if it is sold for research, recognize that the research-use label governs lawful use, which is bona fide laboratory research rather than human consumption. A peptide that is neither an approved drug, nor an eligible compounding substance, nor genuinely confined to research use does not have a lawful human-use pathway, whatever a product page implies. For research-use material, the document that establishes what a vial actually contains is its certificate of analysis, explained in the certificate-of-analysis guide.

Frequently asked questions

Are peptides FDA-approved? Some are. The FDA has approved roughly eighty to one hundred peptide drugs, including insulin and the GLP-1 medications. Most of the peptides discussed in wellness and research settings are not approved drugs; they are either compounded preparations or research-use-only material, neither of which is an approved drug. [1]

Is it legal to buy peptides online? It depends on the category. Buying an FDA-approved peptide drug requires a prescription. A peptide sold for research use only is lawful to buy for bona fide laboratory research, but not for human consumption, and the research-use label does not make human use lawful. [2]

Does a research-use-only label make a peptide legal to use? No. The label permits sale and possession for genuine laboratory research. It does not approve the peptide for human use, and the FDA judges intended use from the full context, not the disclaimer alone. [2] [5]

Are peptides the same as steroids? No. Peptides are short chains of amino acids and are a separate class from anabolic steroids. Some peptides are nonetheless prohibited in regulated sport under anti-doping rules, in the same spirit as steroids. [8]

Do peptides show up on a drug test? In regulated sport, several peptides are on the World Anti-Doping Agency prohibited list and are tested for, so they can result in a sanction. They are not part of a standard employment drug screen. [8]

Did the 2026 FDA news make banned peptides legal? No. The 2026 actions removed certain peptides from an interim restricted compounding category and referred seven to an advisory committee. That changes compounding eligibility rather than approval, and it does not make any peptide a legal drug for human use. [7]

Sources

1. Muttenthaler, M., et al. "Trends in peptide drug discovery." Reviewed figures on FDA-approved peptide drugs (around one hundred). National Library of Medicine, PMC10968328. https://pmc.ncbi.nlm.nih.gov/articles/PMC10968328/
2. Cornell Law School, Legal Information Institute. 21 CFR 201.128, "Meaning of intended uses." https://www.law.cornell.edu/cfr/text/21/201.128
3. Cornell Law School, Legal Information Institute. 21 U.S.C. 321(g), definition of "drug." https://www.law.cornell.edu/uscode/text/21/321
4. Cornell Law School, Legal Information Institute. 21 U.S.C. 355, the new-drug approval requirement. https://www.law.cornell.edu/uscode/text/21/355
5. Food and Drug Administration. Warning Letters (March 31, 2026, to companies marketing research-labeled peptides for human use). FDA Warning Letters index. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
6. Pharmacy Times. "The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means" (a podcast statement is not a rule change). https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means
7. Food and Drug Administration. "Pharmacy Compounding Advisory Committee; Notice of Meeting," July 23 and 24, 2026, docket FDA-2025-N-6895, Federal Register document 2026-07361. https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request
8. World Anti-Doping Agency. The Prohibited List (BPC-157 under S0; peptide hormones and growth factors under S2). https://www.wada-ama.org/en/prohibited-list
9. Food and Drug Administration. Import Alert 66-78 (unapproved peptide drug substances, expanded in 2025) and Import Alert 66-80 (GLP-1 bulk substances, 2026). https://www.accessdata.fda.gov/cms_ia/importalert_1166.html